Correction: Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. BMJ Publishing Group.
Chicago Style (17th ed.) CitationCorrection: Early Decrease of Blood Myeloid-derived Suppressor Cells During Checkpoint Inhibition Is a Favorable Biomarker in Metastatic Melanoma. BMJ Publishing Group.
MLA (9th ed.) CitationCorrection: Early Decrease of Blood Myeloid-derived Suppressor Cells During Checkpoint Inhibition Is a Favorable Biomarker in Metastatic Melanoma. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.